Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jun;87(6):794-797.
doi: 10.1002/ana.25770.

SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad

Sandra Amor  1   2 , David Baker  2 , Samia J Khoury  3   4 , Klaus Schmierer  2   5 , Gavin Giovanonni  2   5
Affiliations
Editorial

SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad

Sandra Amor et al. Ann Neurol. 2020 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

No company was involved in the decision to write or was involved in the content of this paper. S.A. and SJK have no conflicts of interest. D.B. received consultancy/speaker fees from: Canbex Therapeutics, Inmunebio, Lundbeck, Merck, Novartis, and Sanofi Genzyme. K.S. has received consultancy, speaker fees from: Biogen, Merck, Novartis, Roche, Sanofi‐Genzyme, and Teva. G.G. has received consultancy, speaker fees, or research support from: Abbvie, Actelion, Atara, Biogen, Canbex Therapeutics, Celgene, MedDay, Merck, Novartis, Roche, Sanofi‐Genzyme, Takeda, and Teva. G.G. has received consultancy, speaker fees, or research support from: Abbvie, Actelion, Atara, Biogen, Canbex Therapeutics, Celgene, MedDay, Merck, Novartis, Roche, Sanofi‐Genzyme, Takeda, and Teva, and is the Editor of multiple sclerosis and related disorders.

References

    1. WHO . Coronavirus disease 2019 (COVID‐19) situation report – 52. Available at: at https://www.who.int/docs/default-source/ coronaviruse/20200312‐sitrep‐52‐covid‐19. Accessed March 12, 2020.
    1. Coles A, Lim M, Giovannoni G, Anderson P, Dorsey‐Campbell, Qualie M.ABN guidance on the use of disease‐modifying therapies in multiple sclerosis in response to the threat of a coronavirus epidemic. https://cdn.ymaws.com/www.theabn.org/resource/collection/65C334C7‐30FA‐45DB‐93AA‐74B3A3A20293/... for MS_and COVID19 VERSION 4 April 2nd.pdf. Accessed April 2, 2020.
    1. Broadley S, Carrol B, Gerbis, Mason D , Boggild M, Beadnall H, van der Walt A, Lechner‐Scott J, Frith J, Hodgkinson S, Reddel S, Macdonnell R, Barnett M, Marriott M, McCombe P, Kilpatrick T, Taylor B, Kermode A. Advice for patients with multiple sclerosis and related disorders regarding COVID‐19 outbreak. https://www.msnz.org.nz/wp-content/uploads/2020/04/Alert-Level-4-Advice-.... Accessed on March 6, 2020.
    1. Zhu J, Ji P, Pang J, et al. Clinical characteristics of 3,062 COVID‐19 patients: a meta‐analysis. J Med Virol. 2020. 10.1002/jmv.25884 - DOI - PMC - PubMed
    1. Xiong Y, Liu Y, Cao L, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID‐19 patients. Emerg Microbes Infect 2020;9:761–770. 10.1080/22221751.2020.1747363 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances